216 related articles for article (PubMed ID: 21042215)
21. Are guidelines on use of colony-stimulating factors in solid cancers flawed?
Haines IE; Olver I
Intern Med J; 2009 Apr; 39(4):259-62. PubMed ID: 19402867
[TBL] [Abstract][Full Text] [Related]
22. [Guidelines for prevention of febrile neutropenia].
Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
[TBL] [Abstract][Full Text] [Related]
23. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
[TBL] [Abstract][Full Text] [Related]
24. Neutropenia: state of the knowledge part I.
Nirenberg A; Bush AP; Davis A; Friese CR; Gillespie TW; Rice RD
Oncol Nurs Forum; 2006 Nov; 33(6):1193-201. PubMed ID: 17149402
[TBL] [Abstract][Full Text] [Related]
25. Myeloid growth factors.
Crawford J; Armitage J; Balducci L; Becker PS; Blayney DW; Cataland SR; Heaney ML; Hudock S; Kloth DD; Kuter DJ; Lyman GH; McMahon B; Rugo HS; Saad AA; Schwartzberg LS; Shayani S; Steensma DP; Talbott M; Vadhan-Raj S; Westervelt P; Westmoreland M; Dwyer M; Ho M;
J Natl Compr Canc Netw; 2013 Oct; 11(10):1266-90. PubMed ID: 24142827
[TBL] [Abstract][Full Text] [Related]
26. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.
Dinan MA; Hirsch BR; Lyman GH
J Natl Compr Canc Netw; 2015 Jan; 13(1):e1-7. PubMed ID: 25583775
[TBL] [Abstract][Full Text] [Related]
27. Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center.
Abernethy AP; Barbour SY; Uronis H; Zafar SY; Coan A; Rowe K; Pupa MR; Wheeler JL; Herndon JE
Support Care Cancer; 2009 Jun; 17(6):735-44. PubMed ID: 19096882
[TBL] [Abstract][Full Text] [Related]
28. Prophylaxis of febrile neutropenia in adults receiving chemotherapy needs to be adapted to the risk.
Georgala A; Klastersky JA
Expert Rev Hematol; 2015 Feb; 8(1):115-21. PubMed ID: 25431921
[TBL] [Abstract][Full Text] [Related]
29. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
Smith TJ; Bohlke K; Lyman GH; Carson KR; Crawford J; Cross SJ; Goldberg JM; Khatcheressian JL; Leighl NB; Perkins CL; Somlo G; Wade JL; Wozniak AJ; Armitage JO;
J Clin Oncol; 2015 Oct; 33(28):3199-212. PubMed ID: 26169616
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.
Saloustros E; Tryfonidis K; Georgoulias V
Expert Opin Pharmacother; 2011 Apr; 12(6):851-63. PubMed ID: 21254862
[TBL] [Abstract][Full Text] [Related]
32. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?
Klastersky J; Awada A
Crit Rev Oncol Hematol; 2011 Apr; 78(1):17-23. PubMed ID: 20227290
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy dose intensity and quality cancer care.
Lyman GH
Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):16-25. PubMed ID: 17370925
[TBL] [Abstract][Full Text] [Related]
34. A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group.
Lyman GH; Poniewierski MS
J Natl Compr Canc Netw; 2017 Dec; 15(12):1543-1550. PubMed ID: 29223991
[TBL] [Abstract][Full Text] [Related]
35. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Weeks JA; Somerfield MR; Feinglass J; Smith TJ
J Clin Oncol; 1999 Nov; 17(11):3676-81. PubMed ID: 10550166
[TBL] [Abstract][Full Text] [Related]
36. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.
Gridelli C; Aapro MS; Barni S; Beretta GD; Colucci G; Daniele B; Del Mastro L; Di Maio M; De Petris L; Perrone F; Thatcher N; De Marinis F
Crit Rev Oncol Hematol; 2007 Jul; 63(1):53-64. PubMed ID: 17368037
[TBL] [Abstract][Full Text] [Related]
37. Management of chemotherapy-induced neutropenia in the older cancer patient.
Balducci L
Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):26-31. PubMed ID: 17370926
[TBL] [Abstract][Full Text] [Related]
38. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
[TBL] [Abstract][Full Text] [Related]
39. [Use of granulocyte-colony stimulating factor(G-CSF)in patients with cancer at high risk of febrile neutropenia on the basis of high age and complications, recommendations for patients receiving radiotherapy, and adverse events because of G-CSF].
Hanada N; Tanaka S; Takahata T; Sato A
Gan To Kagaku Ryoho; 2014 Jun; 41(6):702-6. PubMed ID: 25129083
[TBL] [Abstract][Full Text] [Related]
40. Issues on the Use of White Blood Cell Growth Factors in Oncology Practice.
Lyman GH
Am Soc Clin Oncol Educ Book; 2016; 35():e528-32. PubMed ID: 27249763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
